Format

Send to:

Choose Destination
See comment in PubMed Commons below
Immunol Allergy Clin North Am. 2012 Nov;32(4):633-69. doi: 10.1016/j.iac.2012.07.001. Epub 2012 Sep 4.

Immunosuppressive therapy for autoimmune lung diseases.

Author information

  • 1UW Lung Transplant & Advanced Pulmonary Disease Program, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. kcm@medicine.wisc.edu

Abstract

This article focuses on issues of safety and monitoring when immunosuppressive pharmacologic therapies are prescribed for the treatment of connective tissue disease (CTD)-associated interstitial pneumonias, vasculitides, and bronchiolitis. Prospective, randomized placebo-controlled clinical trials have yet to be performed to evaluate the efficacy and safety of various immunosuppressive agents used to treat patients with CTD-interstitial lung disease or idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis (idiopathic usual interstitial pneumonia) that are not associated with the presence of CTD. Knowledge of their potential toxicities and interactions with other drugs combined with the adoption of a systematic approach to monitoring therapy can minimize life-threatening reactions.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
23102070
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk